Aquestive Therapeutics (NASDAQ:AQST) Given “Buy” Rating at HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 82.48% from the stock’s current price.

Other analysts have also issued research reports about the company. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Leerink Partners reiterated an “outperform” rating and set a $12.00 price target (up previously from $10.00) on shares of Aquestive Therapeutics in a research note on Monday, September 30th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $8.67.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $5.48 on Friday. The firm has a fifty day moving average price of $4.74 and a two-hundred day moving average price of $3.75. Aquestive Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $6.23. The company has a market cap of $498.89 million, a PE ratio of -13.05 and a beta of 2.85.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.08. The company had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the business posted ($0.10) EPS. Analysts expect that Aquestive Therapeutics will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

A number of large investors have recently bought and sold shares of AQST. Janney Montgomery Scott LLC acquired a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at $1,456,000. SG Americas Securities LLC bought a new position in Aquestive Therapeutics during the 1st quarter valued at about $54,000. Vanguard Group Inc. boosted its position in Aquestive Therapeutics by 71.7% in the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after buying an additional 1,353,518 shares in the last quarter. Lazard Asset Management LLC grew its stake in Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after buying an additional 15,601 shares during the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Aquestive Therapeutics by 219.7% during the first quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock worth $438,000 after buying an additional 70,666 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.